These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2439252)

  • 1. Food-induced gastric retention and absorption of sustained-release procainamide.
    Rocci ML; Mojaverian P; Davis RJ; Ferguson RK; Vlasses PH
    Clin Pharmacol Ther; 1987 Jul; 42(1):45-9. PubMed ID: 2439252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of procainamide and N-acetylprocainamide in rats.
    Kamath BL; Lai CM; Gupta SD; Durrani MJ; Yacobi A
    J Pharm Sci; 1981 Mar; 70(3):299-302. PubMed ID: 6167709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thin-layer chromatographic determination of procainamide and N-acetylprocainamide in human serum and urine at single-dose levels.
    Kark B; Sistovaris N; Keller A
    J Chromatogr; 1983 Oct; 277():261-72. PubMed ID: 6196373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of procainamide and N-acetylprocainamide in biological fluids by high-pressure liquid chromatography.
    Lai CM; Kamath BL; Look ZM; Yacobi A
    J Pharm Sci; 1980 Aug; 69(8):982-4. PubMed ID: 6157019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption kinetics of procainamide in humans.
    Manion CV; Lalka D; Baer DT; Meyer MB
    J Pharm Sci; 1977 Jul; 66(7):981-4. PubMed ID: 886461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation.
    Zema MJ; Mirando T
    Angiology; 1983 Jan; 34(1):32-9. PubMed ID: 6186164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procainamide absorption studies to test the feasibility of using a sustained-release preparation.
    Shaw TR; Kumana CR; Kaye CM; Padgham C; Kaspi T; Hamer J
    Br J Clin Pharmacol; 1975 Dec; 2(6):515-9. PubMed ID: 1234015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate-release and sustained-release procainamide: bioavailability at steady state in cardiac patients.
    Vlasses PH; Rocci ML; Porrini KA; Greenspon AJ; Ferguson RK
    Ann Intern Med; 1983 May; 98(5 Pt 1):613-4. PubMed ID: 6189438
    [No Abstract]   [Full Text] [Related]  

  • 12. More-sensitive enzyme-multiplied immunoassay technique for procainamide and N-acetylprocainamide in plasma, serum, and urine.
    Henry PR; Dhruv RA
    Clin Chem; 1988 May; 34(5):957-60. PubMed ID: 2453309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time.
    Mojaverian P; Rocci ML; Conner DP; Abrams WB; Vlasses PH
    Clin Pharmacol Ther; 1987 Jan; 41(1):11-7. PubMed ID: 3802700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.
    Ylitalo P; Ruosteenoja R; Leskinen O; Metsä-Ketelä T
    Eur J Clin Pharmacol; 1983; 25(6):791-5. PubMed ID: 6198178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat.
    Bruguerolle B; Jadot G
    J Pharm Pharmacol; 1985 Sep; 37(9):654-6. PubMed ID: 2416904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, plasma concentrations and adverse effects of a new sustained release procainamide preparation.
    Giardina EG; Fenster PE; Bigger JT; Mayersohn M; Perrier D; Marcus FI
    Am J Cardiol; 1980 Nov; 46(5):855-62. PubMed ID: 6159783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation].
    Pirovino M; Karlaganis G; Galeazzi RL
    Schweiz Med Wochenschr; 1980 Sep; 110(39):1415-9. PubMed ID: 6169144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of N-acetylprocainamide from mixed diet in rats.
    Kamath BL; Yacobi A; Gupta SD; Stampfli H; Durrani M; Lai CM
    Res Commun Chem Pathol Pharmacol; 1981 May; 32(2):299-308. PubMed ID: 6166034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition.
    Jung D; Nanavaty M; Prasad P
    Drug Metab Dispos; 1985; 13(3):359-63. PubMed ID: 2410212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias.
    Hilleman DE; Patterson AJ; Mohiuddin SM; Ortmeier BG; Destache CJ
    Drug Intell Clin Pharm; 1988; 22(7-8):554-8. PubMed ID: 2458219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.